Retatrutide is a triple hormone receptor agonist of GLP-1, GIP, and GCGR (glucagon) receptors.
It has been shown to achieve a more than 24% mean weight reduction in non-diabetic obese or overweight adults during a phase 2 trial.
Triple G agonists are superior to single or dual agonists for achieving weight loss, reducing hepatic steatosis, and normalizing glucose levels.
Side effects or dose dependent and are predominantly G.I., with nausea occurring in 45 to 60% of patients.
Adverse events lead to discontinuation and 16% of participants.
Efficacy, is present with weight loss in patients with or without diabetes.
In patients with fatty liver disease, it can normalize liver fat content by up to 90% of patients.